<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36930561</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Internet"><Volume>159</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>Anti-Ro52/TRIM21 antibodies are associated with aberrant inflammatory circuits in patients with systemic autoimmune rheumatic diseases.</ArticleTitle><Pagination><StartPage>55</StartPage><EndPage>64</EndPage><MedlinePgn>55-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.M22000739</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Anti-Ro52/TRIM21 antibodies are markers for several systemic autoimmune rheumatic diseases (SARD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether anti-Ro52/TRIM21 antibodies are related to abnormalities in inflammatory circuits.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional study of consecutive outpatients with SARD. Anti-Ro52/TRIM21 antibodies and serum amyloid A protein were measured by ELISA; panels for 18 cytokines and nine chemokines were analyzed on a Luminex reading platform, while high-sensitivity C-reactive protein (hs-CRP) and complement were measured by nephelometry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 167 included patients, 143 had systemic lupus erythematosus (SLE), 16 had primary Sj&#xf6;gren's syndrome and eight had systemic sclerosis; 41 (24%) were positive for anti-Ro52/TRIM21 antibodies. Patients with anti-Ro52/TRIM21 antibodies had higher serum levels of IL-2, IL-4, IL-6, GM-CSF, IL-21, IL-22, hs-CRP and chemokines CCL4, CXCL8, CXCL10 and CXCL12, but lower levels of complement C4. Anti-Ro52/TRIM21 antibody titers were positively correlated with IL-2, IL-4, IL-6, IL-10, IL-21, IL-22, CXCL10, and hs-CRP, and negatively with complements C3 and C4. When only SLE patients were included, no association was identified between anti-Ro52/TRIM21 antibodies and disease activity or organ-specific involvement.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Anti-Ro52/TRIM21 antibodies are associated with aberrant cytokine circuits and elevated levels of angiogenic molecules and neutrophil and monocyte chemoattractants, which suggests an active role for these antibodies in SARD.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amezcua-Guerra</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Immunology Department, Instituto Nacional de Cardiolog&#xed;a "Ignacio Ch&#xe1;vez", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Garc&#xed;a</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Rojas</LastName><ForeName>Valent&#xed;n</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Immunology Department, Instituto Nacional de Cardiolog&#xed;a "Ignacio Ch&#xe1;vez", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe1;rquez-Velasco</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunology Department, Instituto Nacional de Cardiolog&#xed;a "Ignacio Ch&#xe1;vez", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>Luis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Instituto Nacional de Cardiolog&#xed;a "Ignacio Ch&#xe1;vez", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Los anticuerpos anti-Ro52/TRIM21 est&#xe1;n asociados a circuitos inflamatorios aberrantes en pacientes con enfermedades reum&#xe1;ticas autoinmunes sist&#xe9;micas.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">Los anticuerpos anti-Ro52/TRIM21 son marcadores de varias enfermedades reum&#xe1;ticas autoinmunes sist&#xe9;micas (ERAS).</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Evaluar si los anticuerpos anti-Ro52/TRIM21 est&#xe1;n relacionados con anomal&#xed;as en los circuitos inflamatorios.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Estudio transversal de pacientes consecutivos y ambulatorios con ERAS. Los anticuerpos anti-Ro52/TRIM21 y la prote&#xed;na amiloide s&#xe9;rica se midieron mediante ELISA; los paneles para 18 citocinas y nueve quimiocinas se analizaron en una plataforma de lectura Luminex; la prote&#xed;na C reactiva (hs-CRP) y el complemento se midieron mediante nefelometr&#xed;a.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se incluyeron 167 pacientes, 143 con lupus eritematoso sist&#xe9;mico (LES), 16 con s&#xed;ndrome de Sj&#xf6;gren primario y ocho con esclerosis sist&#xe9;mica; 41 fueron positivos para anticuerpos anti-Ro52/TRIM21 (24 %). Los pacientes con anticuerpos anti-Ro52/TRIM21 tuvieron niveles s&#xe9;ricos m&#xe1;s altos de IL-2, IL-4, IL-6, GM-CSF, IL-21, IL-22, hs-CRP y quimiocinas CCL4, CXCL8, CXCL10 y CXCL12; y m&#xe1;s bajos de complemento C4. Los t&#xed;tulos de anticuerpos anti-Ro52/TRIM21 correlacionaron positivamente con IL-2, IL-4, IL-6, IL-10, IL-21, IL-22, CXCL10 y hs-CRP; y negativamente con complemento C3 y C4. Al incluir solo LES, no se identific&#xf3; asociaci&#xf3;n entre los anticuerpos anti-Ro52/TRIM21 y la actividad de la enfermedad o la afectaci&#xf3;n espec&#xed;fica de &#xf3;rganos.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">Los anticuerpos anti-Ro52/TRIM21 se asocian a circuitos aberrantes de citocinas y niveles elevados de mol&#xe9;culas angiog&#xe9;nicas y quimioatrayentes de neutr&#xf3;filos y monocitos, lo que sugiere un papel activo de esos anticuerpos en las ERAS.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-Ro52/TRIM21 antibodies</Keyword><Keyword MajorTopicYN="N">Anticuerpos anti-Ro52/TRIM21</Keyword><Keyword MajorTopicYN="N">Chemokines</Keyword><Keyword MajorTopicYN="N">Citocinas</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Inflamaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Quimiocinas</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>12</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36930561</ArticleId><ArticleId IdType="doi">10.24875/GMM.M22000739</ArticleId><ArticleId IdType="pii">j159/1/55</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>